ARCHIVES

FDA Approval of Abraxane Sets Stage for Competition Between Taxane Drugs. Abraxane a Nanotechnology Drug? Sponsor Says Yes, FDA Says.

This article is from The Cancer Letter archive.

Vol. 31 No. 02 | January 14, 2005

Download PDF Visit The Full Archive

Related Articles

Drugs Available To Investigators Centers to Monitor Them Are Listed

September 9, 1977

Health Organizations: Cancer Center, Organization Join to Promote Awareness Of Skin Cancer

April 11, 1997

NCI, Private Groups, Promote Mammograms To Blacks, Hispanics

April 25, 1992

Clinton R&D Budget Amounts to a Cut, AAAS Study Says

April 18, 1997

DCT Advisors Approve $22 Mil. Set Aside For Interactive R01s Systemic Therapies

July 10, 1992

ODAC Advice: Avoid ESAs In Curative Settings, Require Patients To Sign Informed Consent.

March 14, 2008